Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 1
1966 1
1967 1
1968 4
1969 1
1970 3
1971 3
1972 3
1973 5
1974 2
1975 1
1978 2
1979 2
1980 5
1982 2
1983 7
1984 3
1985 3
1986 2
1987 4
1988 3
1989 8
1990 6
1991 15
1992 11
1993 16
1994 8
1995 13
1996 8
1997 14
1998 7
1999 7
2000 16
2001 27
2002 11
2003 10
2004 16
2005 18
2006 11
2007 13
2008 15
2009 13
2010 21
2011 12
2012 21
2013 16
2014 19
2015 12
2016 16
2017 23
2018 13
2019 19
2020 16
2021 13
2022 22
2023 20
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Results by year

Filters applied: . Clear all
Page 1
Paraganglioma of the Head and Neck: A Review.
Sandow L, Thawani R, Kim MS, Heinrich MC. Sandow L, et al. Endocr Pract. 2023 Feb;29(2):141-147. doi: 10.1016/j.eprac.2022.10.002. Epub 2022 Oct 15. Endocr Pract. 2023. PMID: 36252779 Free PMC article. Review.
OBJECTIVE: To review the epidemiology, presentation, diagnosis, and management of head and neck paragangliomas. METHODS: A literature review of english language papers with focus on most current literature. RESULTS: Paragangliomas (PGLs) are a group of neuroendocrin …
OBJECTIVE: To review the epidemiology, presentation, diagnosis, and management of head and neck paragangliomas. METHODS: A literature …
Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D, Juhlin CC, Falhammar H. Granberg D, et al. J Clin Endocrinol Metab. 2021 Apr 23;106(5):e1937-e1952. doi: 10.1210/clinem/dgaa982. J Clin Endocrinol Metab. 2021. PMID: 33462603 Free PMC article. Review.
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor malignant potential; about 10% to 15% of pheochromocytomas and up to 50% of abdominal paragangliomas will exhibit metastatic behavior. EVIDENCE ACQUISITION: Extensive searches in the PubMed …
CONTEXT: Pheochromocytomas and paragangliomas (PPGLs) are believed to harbor malignant potential; about 10% to 15% of pheochromocytom …
Management of gastric and duodenal neuroendocrine tumors.
Sato Y, Hashimoto S, Mizuno K, Takeuchi M, Terai S. Sato Y, et al. World J Gastroenterol. 2016 Aug 14;22(30):6817-28. doi: 10.3748/wjg.v22.i30.6817. World J Gastroenterol. 2016. PMID: 27570419 Free PMC article. Review.
Type I G-NETs, which are the most common subtype (70%-80% of all G-NETs), are associated with chronic atrophic gastritis, including autoimmune gastritis and Helicobacter pylori associated atrophic gastritis. Type II G-NETs (5%-6%) are associated with multiple endocrine neo …
Type I G-NETs, which are the most common subtype (70%-80% of all G-NETs), are associated with chronic atrophic gastritis, including autoimmu …
Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants.
Taïeb D, Wanna GB, Ahmad M, Lussey-Lepoutre C, Perrier ND, Nölting S, Amar L, Timmers HJLM, Schwam ZG, Estrera AL, Lim M, Pollom EL, Vitzthum L, Bourdeau I, Casey RT, Castinetti F, Clifton-Bligh R, Corssmit EPM, de Krijger RR, Del Rivero J, Eisenhofer G, Ghayee HK, Gimenez-Roqueplo AP, Grossman A, Imperiale A, Jansen JC, Jha A, Kerstens MN, Kunst HPM, Liu JK, Maher ER, Marchioni D, Mercado-Asis LB, Mete O, Naruse M, Nilubol N, Pandit-Taskar N, Sebag F, Tanabe A, Widimsky J, Meuter L, Lenders JWM, Pacak K. Taïeb D, et al. Lancet Diabetes Endocrinol. 2023 May;11(5):345-361. doi: 10.1016/S2213-8587(23)00038-4. Epub 2023 Mar 31. Lancet Diabetes Endocrinol. 2023. PMID: 37011647 Review.
Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predominantly affected by head and neck paragangliomas, which, in almost 20% of patients, might coexist with paragangliomas arising …
Patients with germline SDHD pathogenic variants (encoding succinate dehydrogenase subunit D; ie, paraganglioma 1 syndrome) are predom …
New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms.
Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. Fortunati E, et al. Curr Treat Options Oncol. 2022 May;23(5):703-720. doi: 10.1007/s11864-022-00967-z. Epub 2022 Mar 24. Curr Treat Options Oncol. 2022. PMID: 35325412 Free PMC article. Review.
Current guidelines recommend the use of SSTR imaging to assess disease extension at staging/restaging, follow-up, assessment of response to therapy and selection of patients who may benefit from radionuclide therapy (PRRT). [18F]F-FDG is used for the assessment of high-grade tumo …
Current guidelines recommend the use of SSTR imaging to assess disease extension at staging/restaging, follow-up, assessment of response to …
Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma.
Muth A, Crona J, Gimm O, Elmgren A, Filipsson K, Stenmark Askmalm M, Sandstedt J, Tengvar M, Tham E. Muth A, et al. J Intern Med. 2019 Feb;285(2):187-204. doi: 10.1111/joim.12869. Epub 2019 Jan 15. J Intern Med. 2019. PMID: 30536464 Free article. Review.
Pheochromocytoma and paraganglioma (PPGL) are rare tumours and at least 30% are part of hereditary syndromes. ...Carriers of pathogenic variants should be offered surveillance with annual biochemical measurements of methoxy-catecholamines and bi-annual rapid whole-body mag …
Pheochromocytoma and paraganglioma (PPGL) are rare tumours and at least 30% are part of hereditary syndromes. ...Carriers of pathogen …
Hereditary Pheochromocytoma.
Santos P, Pimenta T, Taveira-Gomes A. Santos P, et al. Int J Surg Pathol. 2014 Aug;22(5):393-400. doi: 10.1177/1066896914537683. Epub 2014 Jun 5. Int J Surg Pathol. 2014. PMID: 24903423 Review.
INTRODUCTION: Pheochromocytomas (PHEO) and paragangliomas (PGL) are rare neuroendocrine tumors with an estimated occurrence of 2 to 5 patients per million per year and an incidence of about 1 per 100 000 in the general population. These tumors may arise sporadically …
INTRODUCTION: Pheochromocytomas (PHEO) and paragangliomas (PGL) are rare neuroendocrine tumors with an estimated occurrence of 2 to …
Sporadic paraganglioma.
Lee JA, Duh QY. Lee JA, et al. World J Surg. 2008 May;32(5):683-7. doi: 10.1007/s00268-007-9360-4. World J Surg. 2008. PMID: 18224469 Review.
Paraganglioma are rare chromaffin cell tumors that develop from the neural crest cells. ...Many are malignant. Medical management of catecholamine-secreting paraganglioma is the same as for pheochromocytoma. Favorably located abdominal paragangliomas can be s …
Paraganglioma are rare chromaffin cell tumors that develop from the neural crest cells. ...Many are malignant. Medical management of …
Metastatic paraganglioma.
Fliedner SM, Lehnert H, Pacak K. Fliedner SM, et al. Semin Oncol. 2010 Dec;37(6):627-37. doi: 10.1053/j.seminoncol.2010.10.017. Semin Oncol. 2010. PMID: 21167381 Free PMC article. Review.
Paragangliomas (PGLs) are chromaffin cell tumors arising from ganglia; when arising in the adrenal gland they are called pheochromocytomas. In recent years the opinion that metastatic disease is rare in PGL had to be revised, particularly in patients presenting with extra- …
Paragangliomas (PGLs) are chromaffin cell tumors arising from ganglia; when arising in the adrenal gland they are called pheochromocy …
529 results